What did @angadsahota24 actually say?
Honestly, this one is tricky to fact-check directly. The transcript captured by the platform appears to be garbled audio, likely background music or a misprocessed clip, rather than coherent speech about peptides. The caption, however, is where the real claims live. The creator states they are skipping a 30% GHK-Cu product because "the website and lab are super sketchy," and dismissing a 7% formulation because it "isn't even made by a dermatologist." Those are the two specific claims worth examining.
Taking the caption at face value, the creator is making sourcing judgments about GHK-Cu topical products based on vendor credibility and professional oversight. That is actually a reasonable consumer concern in an unregulated supplement-adjacent market, and it deserves a serious look.
Does the science back this up?
The underlying skepticism about GHK-Cu sourcing is well-placed, even if the reasoning is incomplete. GHK-Cu (copper peptide GHK) has genuine research behind it, but the topical delivery and concentration questions are far from settled.
GHK-Cu is a naturally occurring tripeptide with documented roles in wound healing, collagen synthesis stimulation, and antioxidant activity. Pickart and Margolina (2018, Cosmetics) reviewed decades of data showing GHK-Cu promotes fibroblast activity and may support skin remodeling. However, a key problem with topical formulations is bioavailability. Peptides above roughly 500 daltons face significant barriers penetrating the stratum corneum. GHK-Cu sits right at the edge of that window.
On concentration specifically, there is no peer-reviewed consensus establishing that 30% is therapeutically superior to 7% in topical applications. Higher percentages may actually create formulation stability problems, since copper peptides can degrade in the presence of certain pH levels and oxidizing agents. The idea that more is automatically better here is not supported by the literature.
- Pickart L, Margolina A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences.
- Gorouhi F, Maibach HI. (2009). Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science.
What did they get wrong (or right)?
The creator gets partial credit and earns some criticism here. Flagging sketchy vendors is correct instinct. The compounded and specialty peptide market has real quality control problems. Third-party testing, certificate of analysis documentation, and licensed compounding pharmacy status matter. Avoiding a vendor whose website raises red flags is reasonable harm reduction.
Where the logic gets shaky is the "not made by a dermatologist" criterion for the 7% product. Dermatologist involvement in formulation is not a regulated quality standard. A dermatologist's name on a product label does not guarantee sterility, accurate concentration, or stability testing. Conversely, a well-run compounding lab without a dermatologist on the masthead can produce a more rigorously tested product. The credential framing is a marketing heuristic, not a quality assurance framework.
The implicit suggestion that 30% is the preferred tier, if that is the reading, also lacks clinical support. No published human trial has established an optimal topical GHK-Cu concentration for any cosmetic or therapeutic outcome.
What should you actually know?
If you are considering topical GHK-Cu, the sourcing question the creator raises is genuinely important, but the criteria for evaluating sources need to be more rigorous than vibes about a website or a dermatologist's name on the label.
Look for third-party certificates of analysis from ISO-accredited labs. Check whether the manufacturer operates under current good manufacturing practice standards. pH stability matters: GHK-Cu is most stable in slightly acidic formulations around pH 5 to 6. Copper peptides are also incompatible with strong acids, vitamin C at high concentrations, and some exfoliants, which affects how any product should actually be used.
On concentration: the published cosmetic research on GHK-Cu typically uses concentrations well below 30%. There is no clinical evidence that higher topical concentrations produce proportionally better outcomes, and some formulation chemists argue that very high concentrations may reduce bioavailability by affecting the peptide's charge interactions with skin proteins.
GHK-Cu is not a treatment for any diagnosed skin disease. It is a cosmetic ingredient with a plausible mechanism and early-stage supportive data. Anyone using it for wound healing or dermatological conditions should be doing so under medical supervision, not based on TikTok sourcing debates.